S-1/A: Aspira Womens Health Seeks $23 Million in Public Offering to Fuel Growth and Innovation

Aspira Womens Health is launching a public offering of up to 50 million units and 50 million pre-funded units to raise capital for working capital and general corporate purposes.

Summary

• Aspira Womens Health is offering up to 50 million units, each consisting of one share of common stock and one warrant, at an assumed price of $0.40 per unit.
• The company is also offering up to 50 million pre-funded units, each consisting of one pre-funded warrant and one warrant, to investors who would otherwise exceed ownership limits.
• The offering aims to raise approximately $17.9 million in net proceeds, or $20.7 million if underwriters fully exercise their over-allotment option.
• The funds will be used for working capital, general corporate purposes, and potentially for acquisitions or investments in complementary businesses.
• The company is focused on growth, innovation, and operational excellence, with a goal to expand its market reach and product offerings in gynecologic health.
• Aspira's commercial portfolio includes OvaWatch and the Ova1Plus workflow, which are used to assess ovarian cancer risk.
• The company is also developing new tests for ovarian cancer (OVAinform) and endometriosis (ENDOinform), leveraging AI and machine learning.
• The company has decreased operating expenses by $1.9 million during the nine months ended September 30, 2024, compared to the same period in 2023.
• The average OvaSuite volume per field sales representative increased by 21% from 917 tests to 1,109 tests for the nine months ended September 30, 2024, compared to the same period in 2023.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as product innovation and strategic partnerships, the financial instability, delisting risk, and dependence on external funding create significant concerns. The overall sentiment is cautiously negative.

Positives

• The company has a strong focus on innovation, developing new AI-enabled assays for gynecologic diseases.
• Aspira has an extensive biospecimen repository, which supports the development of new algorithms and diagnostic tests.
• The company has successfully published studies supporting the use of its OvaWatch test for monitoring adnexal masses.
• Aspira has expanded its distribution agreement with BioReference to include OvaWatch, increasing its market reach.
• The company has secured a government award of up to $10 million to develop a multi-marker blood test for endometriosis.
• The company has seen a 21% increase in average OvaSuite volume per field sales representative.
• The company has decreased operating expenses by $1.9 million during the nine months ended September 30, 2024, compared to the same period in 2023.

Negatives

• The company has incurred significant losses and negative cash flows since inception.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is not in compliance with Nasdaq's Market Value of Listed Securities and bid price requirements, and its securities are subject to delisting.
• The company may not succeed in improving existing or developing additional diagnostic products.
• The company is subject to new FDA regulations for LDTs, which may increase compliance costs and delay market entry for new tests.
• The company is dependent on third-party payers for reimbursement, and changes in reimbursement rates could adversely affect its business.
• The company may not be able to compete successfully in the competitive diagnostics market.

Risks

• The company's ability to continue as a going concern is uncertain due to significant losses and negative cash flows.
• The company may not be able to secure adequate additional capital on acceptable terms.
• The company's business, results of operations, and financial condition could be adversely affected if it is unable to increase the volume of OvaSuite sales.
• Failures by third-party payers to reimburse for the company's products and services or changes in reimbursement rates could materially and adversely affect the company's business.
• The company may not succeed in improving existing or developing additional diagnostic products, and even if it does, the products may not achieve significant commercial market acceptance.
• The company is subject to new FDA regulations for LDTs, which may increase compliance costs and delay market entry for new tests.
• The company's common stock may be delisted from The Nasdaq Capital Market if it fails to comply with continued listing requirements.
• The company may experience immediate and substantial dilution in the net tangible book value per share of common stock you purchase in the offering.
• The company's milestone-based funding from ARPA-H could be delayed or eliminated based on actions from the Trump Administration.

Future Outlook

The company plans to continue to expand its market reach and product offerings in gynecologic health, focusing on growth, innovation, and operational excellence. The company also intends to continue to raise public awareness regarding the higher sensitivity and negative predictive value for ovarian malignancy of Ova 1 as compared to CA-125 and Risk of Ovarian Malignancy Algorithm on its own for women with adnexal masses planned for surgery, as well as the performance of our ML algorithms in detecting ovarian cancer risk in different racial and ethnic populations. The company plans to continue to expand payor coverage for commercial and Federal payors, including Medicaid, as part of its corporate mission to make the best care available to all women. The company will also continue to focus on advocacy for legislation and the adoption of its technology in professional society guidelines to provide broad access to its products and services.

Management Comments

• The company expects its extensive experience with gynecologists and healthcare providers, along with the historical adoption of its OvaSuite tests, to drive growth as it introduces new products.
• The company believes its ability to successfully develop novel AI-enabled assays is superior to others based on its knowledge and extensive experience in designing and successfully launching FDA-cleared and laboratory developed blood tests to aid in the diagnosis of ovarian cancer.

Industry Context

The diagnostics market is competitive, with several companies developing tests for ovarian cancer and endometriosis. The company's focus on AI-enabled assays and its decentralized testing platform positions it to address the growing demand for non-invasive diagnostic tools in gynecologic health.

Comparison to Industry Standards

• The company's Ova1Plus workflow has a sensitivity of 96% with clinical assessment and specificity of 72%, which is comparable to or better than other available tests for ovarian cancer risk assessment.
• The company's OvaWatch test has a negative predictive value of greater than 99.4%, which is a significant improvement over traditional diagnostics.
• The company's focus on multi-marker tests, combining serum proteins, clinical data, and miRNA, is aligned with the industry trend towards more comprehensive and accurate diagnostic tools.
• The company's collaboration with world-class research and academic institutions allows it to leverage additional specimen collections to continue its product innovation, which is a common practice in the industry.
• The company's decentralized testing platform, Aspira Synergy, is a unique approach that allows for global access to its protein biomarker testing, which is not a common practice in the industry.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution due to the public offering.
• Employees may be affected by potential cost-cutting measures.
• Customers may benefit from the company's continued innovation and expansion of product offerings.
• Suppliers may see increased business opportunities as the company grows.
• Creditors may be concerned about the company's financial instability and ability to repay debts.

Next Steps

• The company plans to continue to expand its market reach and product offerings in gynecologic health.
• The company will continue to develop new tests for ovarian cancer (OVAinform) and endometriosis (ENDOinform).
• The company will continue to expand payor coverage for its products.
• The company will continue to advocate for legislation and the adoption of its technology in professional society guidelines.
• The company will work with an ARPA-H Program Manager and the ARPA-H Investor Catalyst Hub in the design, development, and commercial launch of its endometriosis diagnostic test.

Key Dates

Keywords

Ovarian Cancer, Endometriosis, Diagnostic Tests, AI, Machine Learning, Biomarkers, OvaWatch, Ova1Plus, Aspira Synergy, Gynecologic Health